NGM Biopharmaceuticals Inc (DELISTED) (NGM:DL)
1.54
0.00 (0.00%)
USD |
NASDAQ |
Apr 05, 16:00
NGM Biopharmaceuticals Cash from Financing (TTM): 1.775M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.775M |
| September 30, 2023 | 2.387M |
| June 30, 2023 | 35.60M |
| March 31, 2023 | 53.84M |
| December 31, 2022 | 54.23M |
| September 30, 2022 | 55.89M |
| June 30, 2022 | 26.15M |
| March 31, 2022 | 9.848M |
| December 31, 2021 | 149.66M |
| September 30, 2021 | 174.89M |
| June 30, 2021 | 172.32M |
| Date | Value |
|---|---|
| March 31, 2021 | 172.42M |
| December 31, 2020 | 35.54M |
| September 30, 2020 | 11.50M |
| June 30, 2020 | 11.23M |
| March 31, 2020 | 184.34M |
| December 31, 2019 | 180.75M |
| September 30, 2019 | 176.12M |
| June 30, 2019 | 176.68M |
| March 31, 2019 | 0.309M |
| December 31, 2018 | 0.198M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
1.775M
Minimum
Dec 2023
184.34M
Maximum
Mar 2020
88.69M
Average
54.23M
Median
Dec 2022
Cash from Financing (TTM) Benchmarks
| Catalent Inc | 33.00M |
| AIM ImmunoTech Inc | 0.485M |
| Perspective Therapeutics Inc | 167.19M |
| Protalix BioTherapeutics Inc | 10.43M |
| Armata Pharmaceuticals Inc | 59.32M |